INmune Bio (INMB)
(Delayed Data from NSDQ)
$11.84 USD
+0.07 (0.59%)
Updated Apr 30, 2024 04:00 PM ET
After-Market: $11.84 0.00 (0.00%) 5:24 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
INMB 11.84 +0.07(0.59%)
Will INMB be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for INMB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for INMB
Wall Street Analysts Predict a 99% Upside in INmune Bio, Inc. (INMB): Here's What You Should Know
Can INmune Bio, Inc. (INMB) Climb 105% to Reach the Level Wall Street Analysts Expect?
INMB: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Analysts Initiate Coverage: 5 Stocks for Higher Returns
INmune Bio (INMB) Down on Clinical Hold for Alzheimer's Study
Biotech Stock Roundup: ETTX Up on Acquisition Deal, REGN Offers Updates
Other News for INMB
Inmune Bio’s Promising INKmune Therapy and Strong Financials Merit a Buy Rating
INmune Bio provides update on Alzheimer's candidate XPro
INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three Years
INmune Bio provides update on two patients from Phase 1b AD trial
INKmune Program’s Promise in mCRPC Treatment: A High-Risk, High-Reward Investment with a Favorable Safety Profile